Cormorant Asset Management as of Sept. 30, 2024
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 45 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 22.7 | $428M | 8.5M | 50.42 | |
| Vaxcyte (PCVX) | 6.1 | $114M | 1.0M | 114.27 | |
| Arcellx Common Stock (ACLX) | 5.5 | $104M | 1.3M | 83.51 | |
| Longboard Pharmaceuticals In | 4.9 | $93M | 2.8M | 33.33 | |
| Edgewise Therapeutics (EWTX) | 4.8 | $91M | 3.4M | 26.69 | |
| Eyepoint Pharmaceuticals Com New (EYPT) | 3.5 | $67M | 8.3M | 7.99 | |
| Rapport Therapeutics (RAPP) | 3.2 | $60M | 2.9M | 20.48 | |
| Crinetics Pharmaceuticals In (CRNX) | 3.0 | $56M | 1.1M | 51.10 | |
| Praxis Precision Medicines I Com New (PRAX) | 2.7 | $50M | 870k | 57.54 | |
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 2.6 | $49M | 2.4M | 20.63 | |
| Avidity Biosciences Ord (RNA) | 2.6 | $48M | 1.1M | 45.93 | |
| Janux Therapeutics (JANX) | 2.5 | $48M | 1.1M | 45.43 | |
| Bridgebio Pharma (BBIO) | 2.5 | $47M | 1.9M | 25.46 | |
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 2.2 | $41M | 2.5M | 16.60 | |
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 2.2 | $41M | 2.6M | 15.99 | |
| Merus N V (MRUS) | 2.0 | $37M | 740k | 49.96 | |
| Cg Oncology (CGON) | 2.0 | $37M | 975k | 37.73 | |
| Insmed Com Par $.01 (INSM) | 1.9 | $37M | 500k | 73.00 | |
| Biomea Fusion (BMEA) | 1.9 | $36M | 3.6M | 10.10 | |
| Axsome Therapeutics (AXSM) | 1.9 | $36M | 400k | 89.87 | |
| Bioage Labs (BIOA) | 1.8 | $34M | 1.6M | 20.80 | |
| Helix Acquisition Corp Ii Cl A Ord Shs (HLXB) | 1.6 | $30M | 2.9M | 10.45 | |
| Pharvaris N V (PHVS) | 1.4 | $27M | 1.5M | 18.52 | |
| Abivax Sa Sponsored Ads (ABVX) | 1.3 | $25M | 2.1M | 11.52 | |
| Alumis (ALMS) | 1.2 | $23M | 2.1M | 10.68 | |
| Cargo Therapeutics (CRGX) | 1.2 | $22M | 1.2M | 18.45 | |
| Arcutis Biotherapeutics (ARQT) | 1.1 | $22M | 2.3M | 9.30 | |
| Rhythm Pharmaceuticals (RYTM) | 1.1 | $21M | 400k | 52.39 | |
| Biohaven (BHVN) | 1.1 | $20M | 402k | 49.97 | |
| Urogen Pharma (URGN) | 1.0 | $20M | 1.6M | 12.70 | |
| Y Mabs Therapeutics | 1.0 | $19M | 1.5M | 13.15 | |
| Mbx Biosciences (MBX) | 1.0 | $18M | 700k | 25.98 | |
| Tarsus Pharmaceuticals (TARS) | 0.9 | $16M | 500k | 32.89 | |
| Arrivent Biopharma (AVBP) | 0.7 | $14M | 586k | 23.50 | |
| Anaptysbio Inc Common (ANAB) | 0.6 | $12M | 343k | 33.50 | |
| Korro Bio (KRRO) | 0.5 | $8.9M | 266k | 33.42 | |
| Silence Therapeutics Ads (SLN) | 0.4 | $7.3M | 400k | 18.18 | |
| Engene Holdings (ENGN) | 0.3 | $6.6M | 1.0M | 6.60 | |
| Stoke Therapeutics (STOK) | 0.3 | $5.2M | 427k | 12.29 | |
| Neurogene (NGNE) | 0.2 | $4.5M | 107k | 41.96 | |
| Gh Research Ordinary Shares (GHRS) | 0.2 | $4.0M | 593k | 6.69 | |
| Vyne Therapeutics (VYNE) | 0.1 | $2.6M | 1.4M | 1.88 | |
| Verve Therapeutics (VERV) | 0.1 | $1.7M | 350k | 4.84 | |
| Artiva Biotherapeutics (ARTV) | 0.1 | $1.6M | 104k | 15.45 | |
| Rapt Therapeutics | 0.1 | $999k | 497k | 2.01 |
